title: Early and late infectious consequences of adding rituximab to fludarabine and cyclophosphamide in patients with indolent lymphoid malignancies.
abstract: Whether the addition of rituximab to fludarabine and cyclosphosphamide (FC) increases early or late infection risk remains poorly defined. This retrospective analysis of 160 patients treated with FC+/-rituximab found no evidence of increased infection among patients receiving FC+rituximab, providing some evidence of safety for the continued exploration of this regimen.
authors.forename: Constantine
authors.initials: C
authors.lastname: Tam
authors.forename: John F
authors.initials: JF
authors.lastname: Seymour
authors.forename: Michael
authors.initials: M
authors.lastname: Brown
authors.forename: Philip
authors.initials: P
authors.lastname: Campbell
authors.forename: John
authors.initials: J
authors.lastname: Scarlett
authors.forename: Craig
authors.initials: C
authors.lastname: Underhill
authors.forename: David
authors.initials: D
authors.lastname: Ritchie
authors.forename: Rodney
authors.initials: R
authors.lastname: Bond
authors.forename: Andrew P
authors.initials: AP
authors.lastname: Grigg
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects*; D058846:Antibodies, Monoclonal, Murine-Derived; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use; D015331:Cohort Studies; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects*; D004198:Disease Susceptibility; D005260:Female; D006566:Herpesviridae Infections / Q000453:epidemiology / Q000209:etiology; D006801:Humans; D016867:Immunocompromised Host; D007239:Infections / Q000453:epidemiology / Q000209:etiology*; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000150:complications / Q000188:drug therapy*; D008228:Lymphoma, Non-Hodgkin / Q000150:complications / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011020:Pneumonia, Pneumocystis / Q000453:epidemiology / Q000209:etiology; D012306:Risk; D000069283:Rituximab; D014740:Vidarabine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000069283:Rituximab; D003520:Cyclophosphamide; D014740:Vidarabine; C024352:fludarabine